This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tzahar, E.
Right arrow Articles by Yarden, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tzahar, E.
Right arrow Articles by Yarden, Y.

 Previous Article  |  Next Article 

Mol. Cell. Biol., 10 1996, 5276-5287, Vol 16, No. 10
Copyright © 1996, American Society for Microbiology

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

E Tzahar, H Waterman, X Chen, G Levkowitz, D Karunagaran, S Lavi, BJ Ratzkin and Y Yarden
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.

The ErbB family includes four homologous transmembrane tyrosine kinases. Whereas ErbB-1 binds to the epidermal growth factor (EGF), both ErbB-3 and ErbB-4 bind to the Neu differentiation factors (NDFs, or neuregulins), and ErbB-2, the most oncogenic family member, is an orphan receptor whose function is still unknown. Because previous lines of evidence indicated the existence of interreceptor interactions, we used ectopic expression of individual ErbB proteins and their combinations to analyze the details of receptor cross talks. We show that 8 of 10 possible homo-and heterodimeric complexes of ErbB proteins can be hierarchically induced by ligand binding. Although ErbB-2 binds neither ligand, even in a heterodimeric receptor complex, it is the preferred heterodimer partner of the three other members, and it favors interaction with ErbB-3. Selective receptor overexpression in human tumor cells appears to bias the hierarchical relationships. The ordered network is reflected in receptor transphosphorylation, ErbB-2-mediated enhancement of ligand affinities, and remarkable potentiation of mitogenesis by a coexpressed ErbB-2. The observed superior ability of ErbB-2 to form heterodimers, in conjunction with its uniquely high basal tyrosine kinase activity, may explain why ErbB-2 overexpression is associated with poor prognosis.


This article has been cited by other articles:

  • Poon, S. L., Hammond, G. T., Leung, P. C. K. (2009). Epidermal Growth Factor-Induced GnRH-II Synthesis Contributes to Ovarian Cancer Cell Invasion. Mol. Endocrinol. 23: 1646-1656 [Abstract] [Full Text]  
  • Nagumo, Y., Faratian, D., Mullen, P., Harrison, D. J., Hasmann, M., Langdon, S. P. (2009). Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity. Mol Cancer Res 7: 1563-1571 [Abstract] [Full Text]  
  • Tao, Y., Dai, P., Liu, Y., Marchetto, S., Xiong, W.-C., Borg, J.-P., Mei, L. (2009). Erbin regulates NRG1 signaling and myelination. Proc. Natl. Acad. Sci. USA 106: 9477-9482 [Abstract] [Full Text]  
  • Vlotides, G., Cooper, O., Chen, Y.-H., Ren, S.-G., Greenman, Y., Melmed, S. (2009). Heregulin Regulates Prolactinoma Gene Expression. Cancer Res. 69: 4209-4216 [Abstract] [Full Text]  
  • Yamamoto, N., Yamada, Y., Fujiwara, Y., Yamada, K., Fujisaka, Y., Shimizu, T., Tamura, T. (2009). Phase I and Pharmacokinetic Study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese Patients with Solid Tumors. Jpn J Clin Oncol 39: 260-266 [Abstract] [Full Text]  
  • Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
  • Proietti, C. J., Rosemblit, C., Beguelin, W., Rivas, M. A., Diaz Flaque, M. C., Charreau, E. H., Schillaci, R., Elizalde, P. V. (2009). Activation of Stat3 by Heregulin/ErbB-2 through the Co-Option of Progesterone Receptor Signaling Drives Breast Cancer Growth. Mol. Cell. Biol. 29: 1249-1265 [Abstract] [Full Text]  
  • Pedersen, N. M., Breen, K., Rodland, M. S., Haslekas, C., Stang, E., Madshus, I. H. (2009). Expression of Epidermal Growth Factor Receptor or ErbB3 Facilitates Geldanamycin-Induced Down-Regulation of ErbB2. Mol Cancer Res 7: 275-284 [Abstract] [Full Text]  
  • Tao, R.-H., Maruyama, I. N. (2008). All EGF(ErbB) receptors have preformed homo- and heterodimeric structures in living cells. J. Cell Sci. 121: 3207-3217 [Abstract] [Full Text]  
  • Honjo, Y., Kniss, J., Eisen, J. S. (2008). Neuregulin-mediated ErbB3 signaling is required for formation of zebrafish dorsal root ganglion neurons. Development 135: 2615-2625 [Abstract] [Full Text]  
  • Johnston, S., Trudeau, M., Kaufman, B., Boussen, H., Blackwell, K., LoRusso, P., Lombardi, D. P., Ben Ahmed, S., Citrin, D. L., DeSilvio, M. L., Harris, J., Westlund, R. E., Salazar, V., Zaks, T. Z., Spector, N. L. (2008). Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy. JCO 26: 1066-1072 [Abstract] [Full Text]  
  • Pedersen, N. M., Madshus, I. H., Haslekas, C., Stang, E. (2008). Geldanamycin-Induced Down-Regulation of ErbB2 from the Plasma Membrane Is Clathrin Dependent but Proteasomal Activity Independent. Mol Cancer Res 6: 491-500 [Abstract] [Full Text]  
  • Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., Patsavoudi, E. (2008). A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2. J. Biol. Chem. 283: 2031-2041 [Abstract] [Full Text]  
  • Choi, S., Myers, J.N. (2008). Molecular Pathogenesis of Oral Squamous Cell Carcinoma: Implications for Therapy. JDR 87: 14-32 [Abstract] [Full Text]  
  • Garland, L. L., Rankin, C., Gandara, D. R., Rivkin, S. E., Scott, K. M., Nagle, R. B., Klein-Szanto, A. J.P., Testa, J. R., Altomare, D. A., Borden, E. C. (2007). Phase II Study of Erlotinib in Patients With Malignant Pleural Mesothelioma: A Southwest Oncology Group Study. JCO 25: 2406-2413 [Abstract] [Full Text]  
  • Zinner, R. G., Nemunaitis, J., Eiseman, I., Shin, H. J. C., Olson, S. C., Christensen, J., Huang, X., Lenehan, P. F., Donato, N. J., Shin, D. M. (2007). Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer. Clin. Cancer Res. 13: 3006-3014 [Abstract] [Full Text]  
  • Hsu, S.-C., Hung, M.-C. (2007). Characterization of a Novel Tripartite Nuclear Localization Sequence in the EGFR Family. J. Biol. Chem. 282: 10432-10440 [Abstract] [Full Text]  
  • Maegawa, M., Takeuchi, K., Funakoshi, E., Kawasaki, K., Nishio, K., Shimizu, N., Ito, F. (2007). Growth Stimulation of Non-Small Cell Lung Cancer Cell Lines by Antibody against Epidermal Growth Factor Receptor Promoting Formation of ErbB2/ErbB3 Heterodimers. Mol Cancer Res 5: 393-401 [Abstract] [Full Text]  
  • Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., Kamma, M., Friedman, P. N., Gelman, R., Iglehart, J. D., Winer, E. P. (2007). Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer. Clin. Cancer Res. 13: 1198-1207 [Abstract] [Full Text]  
  • Nagashima, T., Shimodaira, H., Ide, K., Nakakuki, T., Tani, Y., Takahashi, K., Yumoto, N., Hatakeyama, M. (2007). Quantitative Transcriptional Control of ErbB Receptor Signaling Undergoes Graded to Biphasic Response for Cell Differentiation. J. Biol. Chem. 282: 4045-4056 [Abstract] [Full Text]  
  • Shyamala, G., Chou, Y.-C., Cardiff, R. D., Vargis, E. (2006). Effect of c-neu/ ErbB2 Expression Levels on Estrogen Receptor {alpha}-Dependent Proliferation in Mammary Epithelial Cells: Implications for Breast Cancer Biology. Cancer Res. 66: 10391-10398 [Abstract] [Full Text]  
  • Hellyer, N. J., Mantilla, C. B., Park, E. W., Zhan, W.-Z., Sieck, G. C. (2006). Neuregulin-dependent protein synthesis in C2C12 myotubes and rat diaphragm muscle. Am. J. Physiol. Cell Physiol. 291: C1056-C1061 [Abstract] [Full Text]  
  • Lanza-Jacoby, S., Burd, R., Rosato, F. E. Jr., McGuire, K., Little, J., Nougbilly, N., Miller, S. (2006). Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer.. Clin. Cancer Res. 12: 6161-6169 [Abstract] [Full Text]  
  • Gordon, M. S., Matei, D., Aghajanian, C., Matulonis, U. A., Brewer, M., Fleming, G. F., Hainsworth, J. D., Garcia, A. A., Pegram, M. D., Schilder, R. J., Cohn, D. E., Roman, L., Derynck, M. K., Ng, K., Lyons, B., Allison, D. E., Eberhard, D. A., Pham, T. Q., Dere, R. C., Karlan, B. Y. (2006). Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status. JCO 24: 4324-4332 [Abstract] [Full Text]  
  • Canto, C., Chibalin, A. V., Barnes, B. R., Glund, S., Suarez, E., Ryder, J. W., Palacin, M., Zierath, J. R., Zorzano, A., Guma, A. (2006). Neuregulins Mediate Calcium-induced Glucose Transport during Muscle Contraction. J. Biol. Chem. 281: 21690-21697 [Abstract] [Full Text]  
  • Kim, W. E., Serrero, G. (2006). PC Cell-Derived Growth Factor Stimulates Proliferation and Confers Trastuzumab Resistance to Her-2-Overexpressing Breast Cancer Cells.. Clin. Cancer Res. 12: 4192-4199 [Abstract] [Full Text]  
  • Swanton, C., Futreal, A., Eisen, T. (2006). Her2-targeted therapies in non-small cell lung cancer.. Clin. Cancer Res. 12: 4377s-4383s [Abstract] [Full Text]  
  • Kauraniemi, P, Kallioniemi, A (2006). Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer.. Endocr Relat Cancer 13: 39-49 [Abstract] [Full Text]  
  • Tang, H., Veldman, M. B., Goldman, D. (2006). Characterization of a Muscle-specific Enhancer in Human MuSK Promoter Reveals the Essential Role of Myogenin in Controlling Activity-dependent Gene Regulation. J. Biol. Chem. 281: 3943-3953 [Abstract] [Full Text]  
  • Xia, W., Bisi, J., Strum, J., Liu, L., Carrick, K., Graham, K. M., Treece, A. L., Hardwicke, M. A., Dush, M., Liao, Q., Westlund, R. E., Zhao, S., Bacus, S., Spector, N. L. (2006). Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers. Cancer Res. 66: 1640-1647 [Abstract] [Full Text]  
  • Ogata, T., Dunbar, A. J., Yamamoto, Y., Tanaka, Y., Seno, M., Kojima, I. (2005). Betacellulin-{delta}4, a Novel Differentiation Factor for Pancreatic {beta}-Cells, Ameliorates Glucose Intolerance in Streptozotocin-Treated Rats. Endocrinology 146: 4673-4681 [Abstract] [Full Text]  
  • Tew, W. P., Kelsen, D. P., Ilson, D. H. (2005). Targeted Therapies for Esophageal Cancer. The Oncologist 10: 590-601 [Abstract] [Full Text]  
  • Burris, H. A. III, Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O'Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., Harris, J. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., Spector, N. L. (2005). Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas. JCO 23: 5305-5313 [Abstract] [Full Text]  
  • Cappuzzo, F., Varella-Garcia, M., Shigematsu, H., Domenichini, I., Bartolini, S., Ceresoli, G. L., Rossi, E., Ludovini, V., Gregorc, V., Toschi, L., Franklin, W. A., Crino, L., Gazdar, A. F., Bunn, P. A. Jr, Hirsch, F. R. (2005). Increased HER2 Gene Copy Number Is Associated With Response to Gefitinib Therapy in Epidermal Growth Factor Receptor-Positive Non-Small-Cell Lung Cancer Patients. JCO 23: 5007-5018 [Abstract] [Full Text]  
  • Gilbertson, R. J. (2005). ERBB2 in Pediatric Cancer: Innocent Until Proven Guilty. The Oncologist 10: 508-517 [Abstract] [Full Text]  
  • Zhou, Y., Brattain, M. G. (2005). Synergy of Epidermal Growth Factor Receptor Kinase Inhibitor AG1478 and ErbB2 Kinase Inhibitor AG879 in Human Colon Carcinoma Cells Is Associated with Induction of Apoptosis. Cancer Res. 65: 5848-5856 [Abstract] [Full Text]  
  • Bazley, L A, Gullick, W J (2005). The epidermal growth factor receptor family. Endocr Relat Cancer 12: S17-S27 [Abstract] [Full Text]  
  • Escher, P., Lacazette, E., Courtet, M., Blindenbacher, A., Landmann, L., Bezakova, G., Lloyd, K. C., Mueller, U., Brenner, H. R. (2005). Synapses Form in Skeletal Muscles Lacking Neuregulin Receptors. Science 308: 1920-1923 [Abstract] [Full Text]  
  • Sussman, C. R., Vartanian, T., Miller, R. H. (2005). The ErbB4 Neuregulin Receptor Mediates Suppression of Oligodendrocyte Maturation. J. Neurosci. 25: 5757-5762 [Abstract] [Full Text]  
  • Christensen, J. G., Vincent, P. W., Klohs, W. D., Fry, D. W., Leopold, W. R., Elliott, W. L. (2005). Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor. Molecular Cancer Therapeutics 4: 938-947 [Abstract] [Full Text]  
  • Jo, M., Thomas, K. S., Marozkina, N., Amin, T. J., Silva, C. M., Parsons, S. J., Gonias, S. L. (2005). Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator. J. Biol. Chem. 280: 17449-17457 [Abstract] [Full Text]  
  • Spector, N. L., Xia, W., Burris, H. III, Hurwitz, H., Dees, E. C., Dowlati, A., O'Neil, B., Overmoyer, B., Marcom, P. K., Blackwell, K. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., Ellis, M. J., Liu, L., Man, A. K., Bremer, T. M., Harris, J., Bacus, S. (2005). Study of the Biologic Effects of Lapatinib, a Reversible Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, on Tumor Growth and Survival Pathways in Patients With Advanced Malignancies. JCO 23: 2502-2512 [Abstract] [Full Text]  
  • Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., Kelsey, S. M., Fyfe, G. (2005). Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer. JCO 23: 2534-2543 [Abstract] [Full Text]  
  • Kochupurakkal, B. S., Harari, D., Di-Segni, A., Maik-Rachline, G., Lyass, L., Gur, G., Kerber, G., Citri, A., Lavi, S., Eilam, R., Chalifa-Caspi, V., Eshhar, Z., Pikarsky, E., Pinkas-Kramarski, R., Bacus, S. S., Yarden, Y. (2005). Epigen, the Last Ligand of ErbB Receptors, Reveals Intricate Relationships between Affinity and Mitogenicity. J. Biol. Chem. 280: 8503-8512 [Abstract] [Full Text]  
  • DiGiovanna, M. P., Stern, D. F., Edgerton, S. M., Whalen, S. G., Moore, D. II, Thor, A. D. (2005). Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients. JCO 23: 1152-1160 [Abstract] [Full Text]  
  • Hendriks, B. S., Orr, G., Wells, A., Wiley, H. S., Lauffenburger, D. A. (2005). Parsing ERK Activation Reveals Quantitatively Equivalent Contributions from Epidermal Growth Factor Receptor and HER2 in Human Mammary Epithelial Cells. J. Biol. Chem. 280: 6157-6169 [Abstract] [Full Text]  
  • Nagy, P., Friedlander, E., Tanner, M., Kapanen, A. I., Carraway, K. L., Isola, J., Jovin, T. M. (2005). Decreased Accessibility and Lack of Activation of ErbB2 in JIMT-1, a Herceptin-Resistant, MUC4-Expressing Breast Cancer Cell Line. Cancer Res. 65: 473-482 [Abstract] [Full Text]  
  • Jackson-Fisher, A. J., Bellinger, G., Ramabhadran, R., Morris, J. K., Lee, K.-F., Stern, D. F. (2004). ErbB2 is required for ductal morphogenesis of the mammary gland. Proc. Natl. Acad. Sci. USA 101: 17138-17143 [Abstract] [Full Text]  
  • Xu, K.-P., Riggs, A., Ding, Y., Yu, F.-S. X. (2004). Role of ErbB2 in Corneal Epithelial Wound Healing. IOVS 45: 4277-4283 [Abstract] [Full Text]  
  • Brown, N., Deb, K., Paria, B. C., Das, S. K., Reese, J. (2004). Embryo-Uterine Interactions via the Neuregulin Family of Growth Factors During Implantation in the Mouse. Biol. Reprod. 71: 2003-2011 [Abstract] [Full Text]  
  • Chan, R., Hardy, W. R., Dankort, D., Laing, M. A., Muller, W. J. (2004). Modulation of Erbb2 signaling during development: a threshold level of Erbb2 signaling is required for development. Development 131: 5551-5560 [Abstract] [Full Text]  
  • Britten, C. D. (2004). Targeting ErbB receptor signaling: A pan-ErbB approach to cancer. Molecular Cancer Therapeutics 3: 1335-1342 [Abstract] [Full Text]  
  • de Melker, A. A., van der Horst, G., Borst, J. (2004). c-Cbl directs EGF receptors into an endocytic pathway that involves the ubiquitin-interacting motif of Eps15. J. Cell Sci. 117: 5001-5012 [Abstract] [Full Text]  
  • Vicogne, J., Cailliau, K., Tulasne, D., Browaeys, E., Yan, Y. T., Fafeur, V., Vilain, J. P., Legrand, D., Trolet, J., Dissous, C. (2004). Conservation of Epidermal Growth Factor Receptor Function in the Human Parasitic Helminth Schistosoma mansoni. J. Biol. Chem. 279: 37407-37414 [Abstract] [Full Text]  
  • Brown, D. J., Lin, B., Holguin, B. (2004). Expression of Neuregulin 1, a Member of the Epidermal Growth Factor Family, Is Expressed as Multiple Splice Variants in the Adult Human Cornea. IOVS 45: 3021-3029 [Abstract] [Full Text]  
  • Ross, J. S., Fletcher, J. A., Bloom, K. J., Linette, G. P., Stec, J., Symmans, W. F., Pusztai, L., Hortobagyi, G. N. (2004). Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein. Mol. Cell. Proteomics 3: 379-398 [Abstract] [Full Text]  
  • Warburton, C., Dragowska, W. H., Gelmon, K., Chia, S., Yan, H., Masin, D., Denyssevych, T., Wallis, A. E., Bally, M. B. (2004). Treatment of HER-2/neu Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/neu and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction. Clin. Cancer Res. 10: 2512-2524 [Abstract] [Full Text]  
  • Hughes, D. P. M., Thomas, D. G., Giordano, T. J., Baker, L. H., McDonagh, K. T. (2004). Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma. Cancer Res. 64: 2047-2053 [Abstract] [Full Text]  
  • Miron, T., Mironchik, M., Mirelman, D., Wilchek, M., Rabinkov, A. (2003). Inhibition of tumor growth by a novel approach: In situ allicin generation using targeted alliinase delivery. Molecular Cancer Therapeutics 2: 1295-1301 [Abstract] [Full Text]  
  • Li, B., Chang, C.-M., Yuan, M., McKenna, W. G., Shu, H.-K. G. (2003). Resistance to Small Molecule Inhibitors of Epidermal Growth Factor Receptor in Malignant Gliomas. Cancer Res. 63: 7443-7450 [Abstract] [Full Text]  
  • She, Q.-B., Solit, D., Basso, A., Moasser, M. M. (2003). Resistance to Gefitinib in PTEN-Null HER-Overexpressing Tumor Cells Can Be Overcome through Restoration of PTEN Function or Pharmacologic Modulation of Constitutive Phosphatidylinositol 3'-Kinase/Akt Pathway Signaling. Clin. Cancer Res. 9: 4340-4346 [Abstract] [Full Text]  
  • Nielsen, U. B., Cardone, M. H., Sinskey, A. J., MacBeath, G., Sorger, P. K. (2003). Profiling receptor tyrosine kinase activation by using Ab microarrays. Proc. Natl. Acad. Sci. USA 100: 9330-9335 [Abstract] [Full Text]  
  • Li, Y., Yu, W.-h., Ren, J., Chen, W., Huang, L., Kharbanda, S., Loda, M., Kufe, D. (2003). Heregulin Targets {gamma}-Catenin to the Nucleolus by a Mechanism Dependent on the DF3/MUC1 Oncoprotein. Mol Cancer Res 1: 765-775 [Abstract] [Full Text]  
  • Ross, J. S., Fletcher, J. A., Linette, G. P., Stec, J., Clark, E., Ayers, M., Symmans, W. F., Pusztai, L., Bloom, K. J. (2003). The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy. The Oncologist 8: 307-325 [Abstract] [Full Text]  
  • Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F. III, Hynes, N. E. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 100: 8933-8938 [Abstract] [Full Text]  
  • Cappuzzo, F., Gregorc, V., Rossi, E., Cancellieri, A., Magrini, E., Paties, C. T., Ceresoli, G., Lombardo, L., Bartolini, S., Calandri, C., De Rosa, M., Villa, E., Crino, L. (2003). Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation With HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC. JCO 21: 2658-2663 [Abstract] [Full Text]  
  • Hendriks, B. S., Opresko, L. K., Wiley, H. S., Lauffenburger, D. (2003). Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis: DISTRIBUTION OF HOMO- AND HETERODIMERS DEPENDS ON RELATIVE HER2 LEVELS. J. Biol. Chem. 278: 23343-23351 [Abstract] [Full Text]  
  • Grunwald, V., Hidalgo, M. (2003). Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. JNCI J Natl Cancer Inst 95: 851-867 [Abstract] [Full Text]  
  • Cho, H. J., Kim, W. K., Kim, E. J., Jung, K. C., Park, S., Lee, H. S., Tyner, A. L., Park, J. H. Y. (2003). Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G996-G1005 [Abstract] [Full Text]  
  • Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., Nicholson, R. I. (2003). Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology 144: 1032-1044 [Abstract] [Full Text]  
  • Calvo, B. F., Levine, A. M., Marcos, M., Collins, Q. F., Iacocca, M. V., Caskey, L. S., Gregory, C. W., Lin, Y., Whang, Y. E., Earp, H. S., Mohler, J. L. (2003). Human Epidermal Receptor-2 Expression in Prostate Cancer. Clin. Cancer Res. 9: 1087-1097 [Abstract] [Full Text]  
  • Labriola, L., Salatino, M., Proietti, C. J., Pecci, A., Coso, O. A., Kornblihtt, A. R., Charreau, E. H., Elizalde, P. V. (2003). Heregulin Induces Transcriptional Activation of the Progesterone Receptor by a Mechanism That Requires Functional ErbB-2 and Mitogen-Activated Protein Kinase Activation in Breast Cancer Cells. Mol. Cell. Biol. 23: 1095-1111 [Abstract] [Full Text]  
  • Habib, A. A., Chun, S. J., Neel, B. G., Vartanian, T. (2003). Increased Expression of Epidermal Growth Factor Receptor Induces Sequestration of Extracellular Signal-Related Kinases and Selective Attenuation of Specific Epidermal Growth Factor-Mediated Signal Transduction Pathways. Mol Cancer Res 1: 219-233 [Abstract] [Full Text]  
  • Nagy, P., Vereb, G., Sebestyen, Z., Horvath, G., Lockett, S. J., Damjanovich, S., Park, J. W., Jovin, T. M., Szollosi, J. (2002). Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J. Cell Sci. 115: 4251-4262 [Abstract] [Full Text]  
  • Yen, L., Benlimame, N., Nie, Z.-R., Xiao, D., Wang, T., Moustafa, A.-E. A., Esumi, H., Milanini, J., Hynes, N. E., Pages, G., Alaoui-Jamali, M. A. (2002). Differential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers. Mol. Biol. Cell 13: 4029-4044 [Abstract] [Full Text]  
  • Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., Seelig, S., Arteaga, C. L. (2002). Herceptin-induced Inhibition of Phosphatidylinositol-3 Kinase and Akt Is Required for Antibody-mediated Effects on p27, Cyclin D1, and Antitumor Action. Cancer Res. 62: 4132-4141 [Abstract] [Full Text]  
  • Wu, W., Graves, L. M., Gill, G. N., Parsons, S. J., Samet, J. M. (2002). Src-dependent Phosphorylation of the Epidermal Growth Factor Receptor on Tyrosine 845 Is Required for Zinc-induced Ras Activation. J. Biol. Chem. 277: 24252-24257 [Abstract] [Full Text]  
  • Justman, Q. A., Clinton, G. M. (2002). Herstatin, an Autoinhibitor of the Human Epidermal Growth Factor Receptor 2 Tyrosine Kinase, Modulates Epidermal Growth Factor Signaling Pathways Resulting in Growth Arrest. J. Biol. Chem. 277: 20618-20624 [Abstract] [Full Text]  
  • Lingohr, M. K., Dickson, L. M., McCuaig, J. F., Hugl, S. R., Twardzik, D. R., Rhodes, C. J. (2002). Activation of IRS-2--Mediated Signal Transduction by IGF-1, but not TGF-{alpha} or EGF, Augments Pancreatic {beta}-Cell Proliferation. Diabetes 51: 966-976 [Abstract] [Full Text]  
  • Chinni, S. R., Sarkar, F. H. (2002). Akt Inactivation Is a Key Event in Indole-3-carbinol-induced Apoptosis in PC-3 Cells. Clin. Cancer Res. 8: 1228-1236 [Abstract] [Full Text]  
  • Bajo, A. M., Schally, A. V., Krupa, M., Hebert, F., Groot, K., Szepeshazi, K. (2002). Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Proc. Natl. Acad. Sci. USA 99: 3836-3841 [Abstract] [Full Text]  
  • Tang, X., Batty, I. H., Downes, C. P. (2002). Muscarinic Receptors Mediate Phospholipase C-dependent Activation of Protein Kinase B via Ca2+, ErbB3, and Phosphoinositide 3-Kinase in 1321N1 Astrocytoma Cells. J. Biol. Chem. 277: 338-344 [Abstract] [Full Text]  
  • Segev, A., Aviezer, D., Safran, M., Gross, Z., Yayon, A. (2002). Inhibition of vascular smooth muscle cell proliferation by a novel fibroblast growth factor receptor antagonist. Cardiovasc Res 53: 232-241 [Abstract] [Full Text]  
  • Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., Arteaga, C. L. (2001). Epidermal Growth Factor Receptor (HER1) Tyrosine Kinase Inhibitor ZD1839 (Iressa) Inhibits HER2/neu (erbB2)-overexpressing Breast Cancer Cells in Vitro and in Vivo. Cancer Res. 61: 8887-8895 [Abstract] [Full Text]  
  • Christensen, J. G., Schreck, R. E., Chan, E., Wang, X., Yang, C., Liu, L., Cui, J., Sun, L., Wei, J., Cherrington, J. M., Mendel, D. B. (2001). High Levels of HER-2 Expression Alter the Ability of Epidermal Growth Factor Receptor (EGFR) Family Tyrosine Kinase Inhibitors to Inhibit EGFR Phosphorylation in Vivo. Clin. Cancer Res. 7: 4230-4238 [Abstract] [Full Text]  
  • Hoffmann, I., Eugene, E., Nassif, X., Couraud, P.-O., Bourdoulous, S. (2001). Activation of ErbB2 receptor tyrosine kinase supports invasion of endothelial cells by Neisseria meningitidis. JCB 155: 133-144 [Abstract] [Full Text]  
  • Moasser, M. M., Basso, A., Averbuch, S. D., Rosen, N. (2001). The Tyrosine Kinase Inhibitor ZD1839 (""Iressa"") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells. Cancer Res. 61: 7184-7188 [Abstract] [Full Text]  
  • Moroni, M., Veronese, S., Schiavo, R., Carminati, O., Sorensen, B. S., Gambacorta, M., Siena, S. (2001). Epidermal Growth Factor Receptor Expression and Activation in Nonseminomatous Germ Cell Tumors. Clin. Cancer Res. 7: 2770-2775 [Abstract] [Full Text]  
  • Sartor, C. I., Zhou, H., Kozlowska, E., Guttridge, K., Kawata, E., Caskey, L., Harrelson, J., Hynes, N., Ethier, S., Calvo, B., Earp, H. S. III (2001). HER4 Mediates Ligand-Dependent Antiproliferative and Differentiation Responses in Human Breast Cancer Cells. Mol. Cell. Biol. 21: 4265-4275 [Abstract] [Full Text]  
  • Chow, N.-H., Chan, S.-H., Tzai, T.-S., Ho, C.-L., Liu, H.-S. (2001). Expression Profiles of ErbB Family Receptors and Prognosis in Primary Transitional Cell Carcinoma of the Urinary Bladder. Clin. Cancer Res. 7: 1957-1962 [Abstract] [Full Text]  
  • Tolcher, A. W. (2001). Novel Compounds in the Therapy of Breast Cancer: Opportunities for Integration with Docetaxel. The Oncologist 6: 40-44 [Abstract] [Full Text]  
  • Pawlowski, V., Revillion, F., Hebbar, M., Hornez, L., Peyrat, J.-P. (2000). Prognostic Value of the Type I Growth Factor Receptors in a Large Series of Human Primary Breast Cancers Quantified with a Real-Time Reverse Transcription-Polymerase Chain Reaction Assay. Clin. Cancer Res. 6: 4217-4225 [Abstract] [Full Text]  
  • Fiorentino, L., Pertica, C., Fiorini, M., Talora, C., Crescenzi, M., Castellani, L., Alemà, S., Benedetti, P., Segatto, O. (2000). Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain. Mol. Cell. Biol. 20: 7735-7750 [Abstract] [Full Text]  
  • Thor, A. D., Liu, S., Edgerton, S., Moore, D. II, Kasowitz, K. M., Benz, C. C., Stern, D. F., DiGiovanna, M. P. (2000). Activation (Tyrosine Phosphorylation) of ErbB-2 (HER-2/neu): A Study of Incidence and Correlation With Outcome in Breast Cancer. JCO 18: 3230-3239 [Abstract] [Full Text]  
  • Aviezer, D., Cotton, S., David, M., Segev, A., Khaselev, N., Galili, N., Gross, Z., Yayon, A. (2000). Porphyrin Analogues as Novel Antagonists of Fibroblast Growth Factor and Vascular Endothelial Growth Factor Receptor Binding That Inhibit Endothelial Cell Proliferation, Tumor Progression, and Metastasis. Cancer Res. 60: 2973-2980 [Abstract] [Full Text]  
  • Ram, T. G., Schelling, M. E., Hosick, H. L. (2000). Blocking HER-2/HER-3 Function with a Dominant Negative Form of HER-3 in Cells Stimulated by Heregulin and in Breast Cancer Cells with HER-2 Gene Amplification. Cell Growth Differ. 11: 173-183 [Abstract] [Full Text]  
  • Spencer, K. S.R., Graus-Porta, D., Leng, J., Hynes, N. E., Klemke, R. L. (2000). ErbB2 Is Necessary for Induction of Carcinoma Cell Invasion by Erbb Family Receptor Tyrosine Kinases. JCB 148: 385-397 [Abstract] [Full Text]  
  • Fernandes, A. M., Hamburger, A. W., Gerwin, B. I. (1999). Dominance of ErbB-1 Heterodimers in Lung Epithelial Cells Overexpressing ErbB-2 . Both ErbB-1 and ErbB-2 Contribute Significantly to Tumorigenicity. Am. J. Respir. Cell Mol. Bio. 21: 701-709 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»